CMS Open Payments · Program Year 2024
Pierre Fabre Pharmaceuticals, Inc.
Pierre Fabre Pharmaceuticals, Inc. reported $53,619.53 in payments to 165 physicians and teaching hospitals across 165 transactions.
- $53.6K
- Total payments
- 165
- Transactions
- 165
- Recipients
- −$5.0K
- General Payments vs PY2023
Pierre Fabre Pharmaceuticals, Inc. reported $53,619.53 in payments to 165 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #1334 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $324.97 per recipient across 3 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
The verdict
Pierre Fabre Pharmaceuticals, Inc. pairs below-median payment volume with a broadly spread payment pattern across many recipients.
- #1334
- of 1,925 companies
- 0.0%
- of all US industry payments
- 0.1%
- paid to its single top recipient
- 3
- payment categories
Release-over-release change
General Payments changed from PY2023 to PY2024
Pierre Fabre Pharmaceuticals, Inc.'s CMS-reported General Payments decreased by $5.0K (−8.5%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.
CMS source labels for this exact identifier: PY2022: PIERRE FABRE PHARMACEUTICALS, INC.PY2023: PIERRE FABRE PHARMACEUTICALS, INC.PY2024: Pierre Fabre Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $58,579.55
- PY2024
- $53,619.53
How Pierre Fabre Pharmaceuticals, Inc. ranks nationally
Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.
Pierre Fabre Pharmaceuticals, Inc.'s total vs. every reporting company
CMS Open Payments, Program Year 2024
$53,620 31st percentile higher than 31% of 1,925 reporting companies
Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Open Payments · 2024
What the Data Shows for Pierre Fabre Pharmaceuticals, Inc.
In Program Year 2024, Pierre Fabre Pharmaceuticals, Inc. reported $53,619.53 in payments to 165 physicians and teaching hospitals across 165 individual transactions, an average of $324.97 per transaction and $324.97 per recipient. That total places Pierre Fabre Pharmaceuticals, Inc. at rank #1334 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
32 transactions worth $44.9K make "Travel and Lodging" the top general-payment category in the 3-category breakdown below, 83.8% of the reported total (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 3 types of general payments, Pierre Fabre Pharmaceuticals, Inc.'s largest category was "Travel and Lodging" at $44.9K - 83.8% of the company's reported total.
How Pierre Fabre Pharmaceuticals, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Travel and Lodging | $44.9K | 32 | 83.8% |
| Food and Beverage | $6.7K | 132 | 12.5% |
| Compensation for Services Other Than Consulting | $2.0K | 1 | 3.7% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $28,820.94 (53.8%) of $53,619.53 in this company's General Payments records across 85 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Pierre Fabre Pharmaceuticals, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Xavier Sanchez Flores
$7,585.81 across 5 reported transactions
- 2
John Browning
$6,389.84 across 7 reported transactions
- 3
Elizabeth Lewis Nieman
$5,615.89 across 5 reported transactions
- 4
Esteban Fernandez Faith
$5,376.70 across 7 reported transactions
- 5
Adelaide Hebert
$3,852.70 across 6 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Payment Size Analysis
Average transaction size: $324.97. Average per recipient: $324.97.
Total Amount
$53,619.53
Avg per Transaction
$324.97
Avg per Recipient
$324.97
Payment Transparency Context
What is the Sunshine Act?
The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.
Industry Total (2024)
$13.9B
across 1,925 companies
Pierre Fabre Pharmaceuticals, Inc. Share
0.0%
#1334 by total payments
Companies with Similar Payment Volumes
Pharmaceutical companies with payment totals similar to Pierre Fabre Pharmaceuticals, Inc.
Frequently Asked Questions
How much did Pierre Fabre Pharmaceuticals, Inc. pay to physicians and hospitals in 2024? ▾
How many physicians received payments from Pierre Fabre Pharmaceuticals, Inc.? ▾
What types of payments did Pierre Fabre Pharmaceuticals, Inc. make? ▾
How does Pierre Fabre Pharmaceuticals, Inc. rank among pharmaceutical companies? ▾
What is the average payment size from Pierre Fabre Pharmaceuticals, Inc.? ▾
Where does the payment data for Pierre Fabre Pharmaceuticals, Inc. come from? ▾
Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.